Oncolytic virotherapy has been recognized as a promising new therapy for cancer for decades but only few viruses have been approved worldwide. The therapeutic potential of oncolytic viruses can be severely restricted by innate and adaptive immune barriers making oncolytic virus clinically inefficient.
To overcome this obstacle, we utilized human adipose-derived stem cells (AD-MSC) loaded with tumor selective CAL1 oncolytic vaccinia virus to generate a new therapeutic agent called SNV1 (SuperNova-1). SNV1 cell-based platform protects and potentiates oncolytic vaccinia virus by circumventing humoral innate and adaptive immune barriers, resulting in enhanced oncolytic virotherapy.
We found no results for “keyword”
Please check for typos. The product you are searching for may not be a standard Levitronix product or is not yet on our site.
Can`t find what you are looking for?
Contact usYour account has been created and a verification email
has been sent to your registered email address.
Please check on the verification link included in the email to activate your account.
Return to Sign InAlready have an account?
Please enter your information below.
Not a member? Create account